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Summary
 
Transgenic mice carrying the 
 
env-pX
 
 region of human T lymphocyte virus type I (HTLV-I)
develop autoimmune arthropathy in high incidence. Adopting the approach that Fas-mediated
apoptosis has a critical function in the elimination of self-reactive T cells, we examined the in-
volvement of this apoptosis in the induction of autoimmunity in HTLV-I transgenic mice.
Splenic T cells derived from the transgenic mice were more resistant to apoptosis induced by
anti-Fas mAb than those of the nontransgenic mice, whereas no appreciable difference in apop-
tosis was detected for thymocytes from either mouse’s type. The resistance of transgenic T cells
may be due to Tax coded in the 
 
pX
 
 region, since Tax mediates the inhibition of anti-Fas–
induced apoptosis in mature T cell line, Jurkat. Among the transgenic mice, the extent of the
resistance to Fas-mediated apoptosis was further enhanced in transgenic T cells with disease.
These results suggest that the escape of self-reactive T cells from Fas-mediated apoptosis in the
periphery, is critical for the development of autoimmune arthropathy in HTLV-I transgenic
mice.
 
A
 
utoimmune diseases are characterized by tissue de-
struction and functional impairments caused by self-
reactive cells that escape self-tolerance (1–3). The diseases
may be initiated by viral infections, and the analyses of
these viruses have advanced the understanding of the mo-
lecular mechanisms involved in autoimmune diseases (1).
There are several proposed mechanisms for the role of the
viruses in the induction of autoimmunity (1). The molecu-
lar mimicry between self-antigens and the viral peptides
may induce the survival of self-reactive cells. In addition,
the production of inflammatory cytokines after viral infec-
tion may stimulate the expansion of self-reactive cells. But,
what determines the initial loss of tolerance to a self-anti-
gen still remains to be elucidated.
Human T lymphocyte virus type I (HTLV-I)
 
1
 
 is an etio-
logic agent of adult T cell leukemia (4–6). HTLV-I may
also be involved in several chronic inflammatory diseases of
presumed autoimmune etiology, such as HTLV-I–associ-
ated myelopathy/tropical spastic paraparesis (HAM/TSP),
HTLV-I–associated uveitis, and HTLV-I–associated arthr-
opathy (HAAP) (7–9). Tax is a 40-kD nuclear protein en-
coded by the 
 
pX
 
 region of HTLV-I, which acts as a tran-
scriptional activator of the viral gene as well as a number of
cellular genes (5, 10–19). The aberrant expression of cellu-
lar genes by Tax is proposed to be essential for the transfor-
mation of T cells (4–6). Tax may also play a role in the
pathogenesis of HTLV-I–associated diseases, presumed as
autoimmune conditions, because it induces such diseases
(Sjögren’s syndrome-like exocrinopathy, inflammatory ar-
thropathy resembling rheumatoid arthritis) in the trans-
genic mice (20, 21).
Self-reactive T cells in peripheral lymphoid tissues are
eliminated by apoptosis mediated by the cell surface recep-
tor Fas/Apo-1/CD95 (22). Accumulating evidence shows
that Fas-mediated apoptosis is a crucial guardian in the
maintenance of self-tolerance in vivo. For instance, the lack
of Fas-mediated apoptosis in 
 
lpr
 
 mice (a mutant strain for 
 
fas
 
gene) leads to the development of various autoimmune dis-
eases including arthropathy (23). In this study, we show
that peripheral T cells of HTLV-I transgenic mice are resis-
tant to Fas-mediated apoptosis, and that the extent of the
resistance correlates with the development of arthropathy
 
1
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death;
HAM/TSP, HTLV-I–associated myelopathy/tropical spastic paraparesis;
HAAP, HTLV-I–associated arthropathy; SEB, staphylococcal enterotoxin.
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in these mice. This resistance may be mediated by the viral
protein Tax because the overexpression of Tax in Jurkat T
cells resulted in anti-Fas–resistant characteristics. Thus, Fas-
mediated apoptosis impaired by Tax may be a determinant
in the initial loss of self-tolerance in the transgenic mice,
resulting in the development of autoimmune arthropathy.
These findings will be discussed in the context of the virus-
induced autoimmune diseases including HTLV-I.
 
Materials and Methods
 
Animals.
 
Transgenic mice with HTLV-I 
 
env-pX
 
 region of the
viral genome with its own long terminal repeat promoter were
employed (21). Original transgenic mice with C3H/HeN back-
ground were back-crossed with BALB/c mice. Female mice of
8–11 generations after back-crossing, were used for the experi-
ments. These mice were kept under the SPF conditions in a clean
room of Animal Research Center (Institute of Medical Science,
University of Tokyo).
 
Clinical Evaluation.
 
Joints of the mice paws were macroscopi-
cally examined for inflammation (swelling and redness) once a
week. The mice with arthritis (RA
 
1
 
) show obvious swelling of
their joints, and those without the disease (RA
 
2
 
) do not have
these manifestations, respectively.
 
Cells and Culture Condition.
 
Primary splenocytes and thy-
mocytes prepared from the mice were cultured in DMEM (NI-
KKEN BIO MED. LAB., Kyoto, Japan) supplemented with 10%
FCS and 2-mercaptoethanol (5.5 
 
3
 
 10
 
2
 
5 
 
M). JPX-9 and JPX/M
cells are derivatives of a human T cell line Jurkat, and have a sta-
bly integrated 
 
tax
 
 and 
 
tax
 
 mutant gene under the control of a
methallothionein promoter, respectively (15). JPX-9 and JPX/M
were cultured in RPMI 1640 (NIKKEN BIO MED. LAB.) sup-
plemented with 10% FCS. For the expression of Tax protein, the
cells were cultured in the presence of CdCl
 
2
 
 (10 
 
m
 
M) at 37
 
8
 
C for
24–48 h.
 
Flow Cytometric Analysis and Cell Survival Assay.
 
For in vivo
activation of T cells, staphylococcal enterotoxin B (SEB, 50 
 
m
 
g/
mouse) was intravenously injected into the mice. 3 d after the in-
jection, spleen cells were isolated from the primed mice. The cells
were then treated with agonistic anti-Fas mAb (RK-8; 1 
 
m
 
g/ml)
at 37
 
8
 
C for 12 h, and viable cells were analyzed by the three-
color flow cytometric analysis (EPICS Elite
 
Ô
 
). The Abs used
were anti-CD3 (2C11) labeled with FITC (PharMingen, San Di-
ego, CA) and anti-V
 
b
 
6 or anti-V
 
b
 
8 labeled with PE (PharMin-
gen). Biotinylated anti-Fas mAb (RK-8) was prepared and used
with streptavidin labeled with APC (Becton Dickinson, San Jose,
CA). For in vitro activation of peripheral T cells, splenocytes
were incubated in the presence of plate-coated anti-CD3 mAb
(2C11; 5 
 
m
 
g/ml) at 37
 
8
 
C for 4 d. Activated peripheral T cells or
thymocytes (4 
 
3
 
 10
 
4
 
 cells/well) in 96-well flat-bottom micro-
plate were treated with anti-Fas mAb (RK-8) at 37
 
8
 
C for 20 h.
Then, the cells were cultured in the presence of 3-[4,5-dimethyl-
ethiazol-2-yl]-2,5-diphenyl tetrazorium bromide for 4 h (MTT
assay), and the absorbance at 595 nm of each culture were mea-
sured. Cell viability was calculated as the ratio of the MTT activ-
ity of the cells treated with anti-Fas mAb relative to those with-
out the treatment. For the flow cytometric analysis of in vitro
activated splenocytes, FITC-labeled anti-CD4, PE-labeled anti-
CD8, and APC-labeled anti–Thy-1 mAbs (PharMingen) were
used.
 
Induction of Activation-induced Cell Death.
 
Splenocytes (4 
 
3
 
 10
 
4
 
cells/ml) were treated with Con A (5 
 
m
 
g/ml) for 3 d, and they
were then cultured in the presence of recombinant human IL-2
(100 IU/ml) for 7 d. These preactivated splenocytes were washed
with culture medium and cultured in 96-well flat-bottom micro-
plate coated with anti-CD3 mAb at 5 
 
m
 
g/ml for 48 h. Cell via-
bility was calculated as the ratio of the MTT activity of the cells
cultured with anti-CD3 mAb relative to those without the treat-
ment.
 
Northern Blotting.
 
Cytoplasmic RNA was extracted from
JPX-9 or JPX/M cells by ISOGEN
 
Ô
 
 according to the instruction
of a supplier (NipponGene, Tokyo, Japan). Cytoplasmic RNA
(20 
 
m
 
g) was then applied to 1% agarose gel and size-fractionated
by the electrophoresis in the presence of 2.2 M formaldehyde,
transferred to a nylon membrane and hybridized with radiola-
beled 
 
tax
 
 cDNA. After stringent washing, the membrane was ex-
posed to x-ray film.
 
Gel-Mobility Shift Assay.
 
For the preparation of nuclear ex-
tract, cells (1 
 
3
 
 10
 
7
 
) were washed with phosphate-buffered saline
containing 1 mM Na
 
3
 
VO
 
4
 
, 5 mM NaF. The cells were then
treated with 0.2% NP-40 in lysis buffer (20 mM Hepes [pH 7.9],
20 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM EDTA, 1 mM EGTA, 1 mM
DTT, 0.5 mM PMSF, 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml aprotinin).
After centrifugation, the pellets were further treated with lysis
buffer supplemented with 420 mM NaCl, 20% glycerol for 4
 
8
 
C
for 30 min and centrifugation was repeated. The resulting super-
natant was used as nuclear extract in a gel-mobility shift assay. 10
 
m
 
g of nuclear extract was preincubated with 1 
 
m
 
g of poly(dI:dC)
in 20 
 
m
 
l of binding buffer consisting of 13 mM Hepes (pH 7.9),
65 mM NaCl, 0.15 mM EDTA, 8% glycerol, and 1 mM DTT
for 15 min on ice. Approximately 1 ng of labeled oligonucleotide
was added to the reaction mixture, and further incubated for 15
min at 25
 
8
 
C. Complexes formed were separated from the un-
bound probe by the electrophoresis in 5% polyacrylamide gel
containing 0.5
 
3
 
 TBE, and 2.5% glycerol, dried and then the gel
was exposed to x-ray film. A double-stranded synthetic oligonu-
cleotide corresponding to the NF-
 
k
 
B binding site (top strand:
AGCTTTGGGAAATTCCTCGGGTGGTAC) from the 
 
inter-
feron
 
 gene, was labeled with 
 
g
 
-[
 
32
 
P]ATP by polynucleotide ki-
nase, and employed as the 
 
k
 
B-site probe.
 
Results
 
Peripheral T Cells in HTLV-I env-pX Transgenic Mice Are
Resistant to Agonistic Anti-Fas mAb.
 
HTLV-I transgenic
mice that carry the 
 
env-pX
 
 gene develop inflammatory ar-
thropathy in high incidence (21). We first examined the
sensitivity of peripheral T cells prepared from these trans-
genic mice to Fas-mediated apoptosis. Since fresh primary
T cells from periphery are refractory to anti-Fas treatment,
SEB which activates T cells carrying the TCR V
 
b
 
8 by the
superantigen mechanism, was injected into the transgenic
mice with arthritis. SEB-activated V
 
b
 
8
 
1
 
 T cells in normal
mice are reportedly sensitive to Fas-mediated apoptosis
(24). Splenic T cells isolated 3 d after the SEB injection
were treated with anti-Fas mAb in vitro. The expression of
V
 
b
 
8 and CD3 in these cells was analyzed by the flow cy-
tometry. The injection of SEB increased the population of
V
 
b
 
8
 
1
 
 cells among CD3
 
1
 
 cells in both the control and
transgenic mice (data not shown), consistent with the pre-
vious observation (25). The treatment with anti-Fas mAb
reduced the population of V
 
b
 
8
 
1
 
 T cells in the control mice
from 11.7 to 4.6% probably due to apoptosis, whereas there 
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was little effect on cells from the transgenic mice (Fig. 1 
 
A
 
).
Apoptosis was specific to the activated T cells, since V
 
b
 
6
 
1
 
cells, another T cell subpopulation which was not activated
by SEB, were unaffected by anti-Fas treatment. The resis-
tance of V
 
b
 
8
 
1
 
 T cells prepared from the transgenic mice
was not due to the inefficient expression of Fas on these
cells, since equivalent amounts of Fas were detected on
V
 
b
 
8
 
1
 
 T cells from both the nontransgenic and the trans-
genic mice (Fig. 1 
 
B
 
). To examine the sensitivity of T cell
subsets other than V
 
b
 
8
 
1
 
, splenocytes from the transgenic
mice were preactivated with immobilized anti-CD3 mAb
which can activate T cells in the spleen, followed by the
treatment with anti-Fas mAb. Subsequently, 
 
z
 
90% of the
cells expressed Thy-1 4 d after anti-CD3 treatment (data
not shown), indicating that the majority of cells were the T
cell population. More than 80% of splenic cells derived
from the transgenic mice survived after the treatment with
anti-Fas mAb at the concentration of 1 
 
m
 
g/ml in compari-
son with less than 50% from nontransgenic mice (Fig. 2 
 
A
 
).
Low doses of the anti-Fas mAb (1.6 ng/ml, 8 ng/ml) was
still effective on T cells from the nontransgenic mice, but
had little effect on the viability of T cells from the trans-
genic mice. Like SEB-responsive V
 
b
 
8
 
1
 
 T cells, anti-CD3–
activated T cells derived from these two type of mice ex-
pressed similar amounts of Fas, indicating that the variation
in the sensitivity to anti-Fas mAb is regulated by the fac-
tor(s) downstream from Fas in HTLV-I transgenic mice.
This is completely different from lpr mice that have little
Figure 2. Anti-CD3–activated mature T cells from the transgenic mice were resistant to Fas-mediated apoptosis. (A) Splenocytes from Tg2 mice (open
circle) and Tg1 mice with arthritis (closed circle) were activated with immobilized anti-CD3 mAb for 4 d, and then treated with anti-Fas at the indicated
concentrations for 20 h. Cell viabilities were measured by the MTT assay, and Cell Viability (% of control) indicates the MTT activity in cells treated with
the Ab relative to that without the treatment. data are means of triplicate determinations and are the representative of five independent reproducible stud-
ies. (B) Splenocytes from Tg2 mice and Tg1 mice were activated with immobilized anti-CD3 mAb for 4 d, and then treated with anti-Fas for 12 h. The
activated splenocytes prepared from these mice were treated with anti-Fas mAb (RK-8; 1 mg/ml) in vitro, and then analyzed for the expression of CD4
and CD8 by the flow cytometry. The proportions of CD41 and CD81 T cells population are indicated. The population indicated by an arrow was
CD4lowCD81 cells discussed in the text. The expression of Fas on the cells was also analyzed by flow cytometry.
Figure 1. SEB-responsive splenic T cells of HTLV-I transgenic mice
are resistant to Fas-mediated apoptosis. (A) SEB (50 mg/mouse) was in-
jected intravenously into the transgenic (Tg1) and the nontransgenic mice
(Tg2). Spleen cells prepared from these mice were treated with anti-Fas
mAb (RK-8; 1 mg/ml) in vitro for 12 h, and then analyzed for the ex-
pression of CD3, Vb8, and Vb6 by the flow cytometry. The proportions
of Vb81CD31 or Vb61CD31 T cells population are indicated. (B) SEB
(50 mg/mouse) was injected intravenously into Tg1 and the Tg1 mice.
The expression of Fas (M.C., mean channel) on T cells prepared from the
primed mice were analyzed by the flow cytometry using anti-Fas mAb.60 Apoptosis Resistance and Autoimmune Arthritis Development
Fas expression level because of fas gene mutation. There
are mainly two subsets of T cells (CD41CD82, CD42CD81
T cells) in the spleen. The population of anti-CD3 acti-
vated CD41CD82 and CD42CD81 cells (for 4 d) from the
control mice were reduced by the treatment with anti-Fas
mAb from 30.3 to 16.6% and 8.7 to 5.1 %, respectively,
while those from the transgenic mice were unaffected (Fig.
2 B). Thus, both CD41CD82 and CD42CD81 T cell sub-
sets classified as mature T cells in the transgenic mice, are
less sensitive to Fas-mediated apoptosis than those from the
nontransgenic mice. We always observed that the number
of CD4lowCD82 (with a lower CD4 intensity than CD41
CD82 cells) increase 12 h after anti-Fas treatment. Since
this population increases proportionally with the extent of
apoptosis of CD41CD82 cells, it probably represents apop-
totic CD41CD82 cells.
Since Fas-mediated apoptosis is said to occur not only in
peripheral T cells but also in thymocytes (22), we next ex-
amined the sensitivity of thymocytes to anti-Fas mAb. Un-
like splenic T cells, preactivation was not required to sensi-
tize thymocytes to anti-Fas mAb (Fig. 3). Thymocytes
from the transgenic mice showed similar sensitivity to anti-
Fas mAb as those from the nontransgenic mice (Fig. 3).
This was in contrast to the resistance of splenic T cells from
the transgenic mice to Fas-dependent apoptosis (Figs. 1 A
and 2). Since thymocytes and splenocytes from the trans-
genic mice expressed equivalent amounts of the tax/env
mRNA (26) (data not shown), the difference in the sensi-
tivity to anti-Fas mAb was not due to their altered trans-
gene expression.
Tax inhibits Fas-mediated Cell Death in Jurkat T Cell Line.
Copeland et al. (27) showed that Tax in the pX region in-
hibits apoptosis mediated by Fas using immortalized T cell
lines. To confirm their results in our own assay system, we
used JPX-9, a stable transfectant of Jurkat T cell line that
has the inducible tax gene under the control of a methal-
lothionein promoter (15). Addition of CdCl2 to culture
medium induced the expression of the tax mRNA in JPX-9
cells as well as in JPX/M cells that carry the mutant tax
gene (Fig. 4 A). Tax reportedly induces a NF-kB transcrip-
tion factor complex in T cells. The gel-mobility shift assay
showed that CdCl2 treatment for 24 h induced a complex
specific to the kB sequence in JPX-9 cells, but not in JPX/M
cells (Fig. 4 B), indicating that functional Tax protein was
Figure 3. Thymocytes from the transgenic mice are sensitive to Fas-
mediated apoptosis. Thymocytes were prepared from Tg2 (open circle) and
Tg1 mice (closed circle). They were then treated with the indicated con-
centration of anti-Fas mAb for 20 h. Cell viabilities were measured by the
MTT assay. Cell Viability (% of control) indicates the MTT activity in thy-
mocytes treated with the Ab relative to that without the treatment. Data
are means of triplicate determinations and are the representative of five
independent reproducible studies.
Figure 4. Tax inhibits Fas-mediated apoptosis in Jurkat T cell line. (A)
JPX-9 and JPX/M cells were cultured in the absence (lanes 1 and 4) and
presence (lanes 2, 3, 5, and 6) of 10 mM CdCl2 at 378C for 24–48 h.
RNA was extracted from these cells, and the expression of the tax gene
and the GAPDH gene in the extracted RNA was analyzed by the North-
ern blotting. (B) Nuclear extract was prepared from JPX-9 (lanes 2–5)
and JPX/M cells (lanes 6 and 7) treated with (lanes 3–5) or without
CdCl2 (lanes 1, 2, 6). The NF-kB activity in the nuclear extract was ana-
lyzed by the gel mobility shift assay. Binding reaction was carried out in
the absence (lanes 1–3, 6, and 7) or presence of 100 ng of cold oligonu-
cleotides of AP-1 binding sites (lane 4) or homologous NF-kB binding
site (lane 5). The three complexes indicated by arrow were specific to the
kB sequence, and the upper one, but not the other two, was induced by
the expression of wild-type Tax. (C) JPX-9 and JPX/M treated with or
without CdCl2 were incubated with the indicated concentration of anti-
Fas mAb (CH-11) for 20 h. Cell viability (% of control) indicates the MTT
activity in cells treated with the Ab relative to that without the treatment.
Data are means of triplicate determinations and are the representative of
three independent reproducible studies.61 Kishi et al.
expressed only in JPX-9 cells by CdCl2 treatment. The
binding specificity was confirmed by the selective inhibi-
tion of the induced complex by the homologous kB oligo-
nucleotide, but not by unrelated ones (Fig. 4 B). CdCl2 treat-
ment for 24 h reduced cell death mediated by anti-Fas mAb
(CH-11) in JPX-9 cells at two different concentrations of
the Ab (Fig. 4 C). This was due to the expression of Tax,
but not by CdCl2 treatment, since the reduction was not
observed in JPX/M with the mutant tax gene even after
the treatment with CdCl2. These results indicate that Tax
possesses the inhibitory activity to Fas-mediated apoptosis.
Enhanced Resistance to Fas-mediated Apoptosis of the T Cells
in the Transgenic Mice with Arthritis. SEB was injected into
the nontransgenic mice (Tg2) and the transgenic mice with
arthritis (Tg1RA1) or without arthritis (Tg1RA2), and
then Vb81 T cells prepared from these mice were exam-
ined for their sensitivity to Fas-mediated apoptosis. The
Vb81 T cells from Tg1RA2 mice were more resistant to
anti-Fas mAb than those from Tg2 mice, but their resis-
tance were less than those from Tg1RA1 mice (Fig. 5 A).
The difference between Tg1RA2 mice and Tg1RA1 mice
was not due to variation in the mice, since Vb81 T cells
prepared from 13 animals showed a positive correlation be-
tween the resistance to the induction of apoptosis and dis-
ease development (Fig. 5 A). The treatment with anti-Fas
mAb did not reduce the population of Vb61 T cells that
are not activated by SEB, indicating that the apoptosis in-
duction as well as the inhibition is specific to activated T
cells. In addition to Vb81 T cells, preactivated T cells with
anti-CD3 mAb, derived from the Tg1RA1 mice were
more resistant to Fas-mediated apoptosis than those from
the Tg1RA2 mice (Fig. 5 B). These results suggest that the
sensitivity of activated peripheral T cells to Fas-mediated
apoptosis reduces in accompaniment with the disease de-
velopment in HTLV-I transgenic mice.
Impairment of Anti-CD3–induced Apoptosis in Activated T
Cells Derived from the Transgenic Mice with Arthritis. Self-reac-
tive T cells are eliminated by apoptosis induced by the acti-
vation through their TCR. This phenomenon was designated
as activation-induced cell death (AICD), and Fas-mediated
apoptosis plays a critical role in this AICD process (28).
Therefore, we next examined the sensitivity of activated T
cells to TCR-mediated apoptosis. Splenocytes prepared
from the mice were treated with a T cell mitogen, Con A,
for 3 d, and then cultured in the presence of IL-2 for 7 d.
These preactivated T cells were restimulated with anti-
CD3 mAb which induces AICD to the T cells. The re-
stimulation with anti-CD3 mAb reduced the viability of
the T cells from Tg1 mice, but the reduction was less than
those from Tg2 mice. Moreover, the resistance to anti-
CD3 mAb was enhanced in the T cells from Tg1RA1 rel-
ative to those from Tg1RA2 (Fig. 6). The enhancement of
the resistance to AICD was consistently observed for five
Tg1RA1 mice (data not shown). These results suggested
that the transgenic T cells are more resistant to AICD, and
Figure 5. Enhanced resistance to Fas-mediated apoptosis in T cells derived from the transgenic mice with arthritis. (A) SEB (50 mg/mouse) was intra-
venously injected into Tg2, Tg1RA1, and Tg1RA2 mice. The splenocytes prepared from the SEB-primed mice were treated with anti-Fas for 20 h at
378C. The expression of CD3 and either Vb8 or Vb6 in the cells before and after the treatment with anti-Fas mAb, were determined by the flow cyto-
metric analysis. Vb81 or Vb61 T cells (% of total T cells) indicates the proportion of these cells among the population of CD31 T cells. (B) Splenocytes pre-
pared from the mice, were activated with immobilized anti-CD3 mAb for 4 d, and then treated with anti-Fas mAb at the indicated concentrations for 20 h.
Cell Viability (% of control) indicates the MTT activity in cells treated with the Ab relative to those without this treatment. Data are means of triplicate de-
terminations and are the representative of five independent reproducible studies.
Figure 6. Impairment of acti-
vation-induced cell death in T
cell from the transgenic mice.
Splenocytes prepared from the
mice, were activated with Con A
for 3 d, and then cultured with
IL-2 for 7 d. Activated spleno-
cytes were restimulated with im-
mobilized anti-CD3 mAb for 48 h.
Cell Viability (% of control) indi-
cates the MTT activity in cells
treated with the Ab relative to
those without this treatment.
Data are means of triplicate de-
terminations and are the repre-
sentative of three independent
reproducible studies.62 Apoptosis Resistance and Autoimmune Arthritis Development
the resistance is enhanced with the disease development in
HTLV-I transgenic mice.
Discussion
Several lines of evidence indicate that the autoimmune
mechanism may be a critical step in the development of ar-
thropathy in the transgenic mice carrying the HTLV-I env-pX
gene (26). The transgenic mice produce autoantibodies to
type II collagen, IgG, and heat shock proteins. The admin-
istration of exogenous type II collagen increases the fre-
quency of arthropathy development in the transgenic mice.
The primary determinant for the survival of the self-reac-
tive cells in these mice, however, remains to be elucidated.
In this study, we show that peripheral T cells derived from
HTLV-I transgenic mice are resistant to Fas-mediated apop-
tosis as well as AICD induced by anti-CD3 mAb, and their
susceptibility to this apoptosis inversely correlated with the
development of arthropathy in the mice (Figs. 1, 2, 5 and
6). The lack of Fas-mediated apoptosis observed in lpr (fas
mutant) and in gld (fas ligand mutant) mice causes various
autoimmune diseases by the inability to eliminate self-reac-
tive T cells (23, 29, 30). Therefore, our present results sug-
gest that impaired Fas-mediated apoptosis is a determinant
for the survival of self-reactive T cells and thereby the de-
velopment of autoimmune arthropathy in HTLV-I trans-
genic mice.
There are two main systems for the elimination of self-
reactive T cells; one for immature T cells in thymus, and
the other for mature T cells in peripheral lymphoid tissues
such as spleen. Splenic T cells, but not thymocytes, derived
from the transgenic mice were resistant to Fas-mediated
apoptosis (Fig. 3). Indeed, single positive mature T cells
carrying the transgene resisted apoptosis (Fig. 2 B). Thus,
the impaired elimination of mature self-reactive T cells in
peripheral lymphoid tissues may play a role in the autoim-
munity induction in the transgenic mice.
Fas-mediated apoptosis plays a critical role in elimination
of self-reactive T cells in peripheral lymphoid tissues, but it
may not be the only determinant, because apoptosis in-
duced by TNF may play a role in this process (31). Recent
findings showed that the induction of NF-kB activity in-
hibits apoptosis induced by TNF (32–34), but not by anti-
Fas mAb (34). Since Tax induces NF-kB activity (Fig. 4 B), it
may also inhibit the TNF-induced apoptosis. However, it
is difficult to examine the activity of Tax to TNF-induced
apoptosis because TNF by itself activates NF-kB in most of
cell lines including JPX-9 and Tax activates the expression
of TNF gene. Therefore, further analysis is required to deter-
mine the involvement of TNF-induced apoptosis in the elim-
ination of self-reactive T cells in HTLV-I transgenic mice.
Among the proteins coded in the pX region of HTLV-I,
Tax displayed the inhibitory activity to Fas-mediated apop-
tosis in Jurkat T cells (Fig. 4 C) (27). Therefore, the Tax
activity may explain the resistant phenotype of T cells car-
rying this transgene. However, this may not explain the
enhanced resistance of T cells from mice with arthritis rela-
tive to those without disease (Fig. 5), since both types of
mice equivalently expressed the transgene in spleen (26).
There are at least two possible mechanisms to explain the
enhanced resistance in Tg1RA1 mice: first, other factor(s)
apart from Tax may be involved in the resistance to Fas-
mediated apoptosis. Therefore, such cellular factors and
Tax may collaboratively contribute to the prevention of
Fas-mediated apoptosis in activated mature T cells. Second,
unlike spleen, the expression of Tax is more enhanced in
the mouse joints with arthritis in comparison to those without
disease (26). Consequently, Tax-inducible soluble factor(s)
in the affected joints may circulate to the spleen, changing
the sensitivity of splenic T cells to Fas-mediated apoptosis.
In addition to the inhibition of apoptosis, Tax has vari-
ous activities on cells. Therefore, we can not exclude the
possibility for the contribution of other cofactors or accel-
erators with Tax to develop autoimmune arthritis. Most
notably, Tax can affect the IL-2 autocrine loop and im-
mortalize T cells in the presence of IL-2 in vitro (12, 35).
Therefore, once self-reactive T cells escape the Fas-medi-
ated surveillance system, they may be further expanded by
the immortalization function of Tax. Furthermore, Tax ac-
tivates the transcription of a number of cytokine genes such
as TNF-a, IL-6, and IL-8 (5, 18, 19). These cytokines may
play a role as executioners in the inflammatory response as
well as the proliferation of synovial fibroblasts observed in
the affected joints of the mice. Among the cytokines,
TNF-a is especially noteworthy, since it induces inflam-
matory arthritis in the transgenic mice (36). Taken to-
gether, the cooperation of multiple Tax-inducible func-
tions including the inhibition of peripheral T cell apoptosis
via Fas may be necessary for the development of arthritis in
HTLV-I transgenic mice.
In some HTLV-I–associated diseases such as HAM/TSP,
anti-DNA or anti-immunoglobulin antibodies as well as
increased numbers of self-reactive T cells are detected in
patient sera. This indicates that the autoimmunity may play
a role in the pathogenesis of these HTLV-I–associated dis-
eases in human as well as in the transgenic mice (8, 37, 38).
Accordingly, we are currently studying the involvement of
Fas-mediated apoptosis in these human diseases.
A number of viruses are suggested to be involved in au-
toimmune diseases, but the mechanism of the autoimmu-
nity induced by the virus infection remains to be elucidated
(1). Various viruses encode anti-apoptotic proteins such as
an E1B for an adenovirus (39) and BHRF1 for an Epstein-
Barr virus (40). Perhaps, the viral protein-mediated inhibi-
tion of apoptosis could also be involved in autoimmune
diseases induced by viruses other than HTLV-I.
We thank Y. Nishimura, Y. Yamasaki, and T. Tsukahara for technical assistance, M. Nakamura for helpful
discussion and advice, and T. Imaoka for the manuscript preparation.63 Kishi et al.
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